Objective. Sarcoidosis is a systemic inflammatory disorder characterized by granulomas. Although the aetiology is unknown, sarcoidosis is thought to be mediated by Th1 lymphocytes. Recently, IL-17A has been implicated in granuloma formation in various diseases, including tuberculosis. Therefore, we hypothesized that Th17 cells play a role in sarcoidosis, paralleling recent findings in autoimmune diseases such as RA. The aim of our study was to investigate the role of Th17 cells in sarcoidosis.
Introduction
Sarcoidosis is a systemic inflammatory disease characterized by the presence of non-caseating granulomas in various organs with pulmonary involvement in >90% of patients [1] .
These granulomas are compact, organized collections of macrophages and epithelioid cells, surrounded by and infiltrated with CD45RO + memory T lymphocytes. Besides granulomas, pulmonary alveolitis and peripheral blood lymphopenia are typically present in sarcoidosis [1] . The pathological processes that result in granulomatous inflammation are largely unknown. Nevertheless, the findings of CD4 + T-cell accumulation, oligoclonal TCR-ab mycobacterial infection-induced granuloma in the lung [4] . Although IL-17A can be produced by various cell types, it is the main cytokine produced by the novel subset of Th17 cells, which is distinct from the Th1 and Th2 subsets. Th17 cells were shown to be crucially involved in many autoimmune diseases, including RA, IBD, multiple sclerosis, autoimmune uveitis and in allergic lung disease [58] . Th17 cells have the capacity to confer protection against extracellular bacterial and fungal pathogens such as Klebsiella pneumoniae, Citrobacter rodentium and Candida albicans, although accumulating evidence demonstrates that Th17 cells also provide protective effects during infection with more traditional intracellular pathogens [4, 9] . Interestingly, there are many reports of sarcoidosis co-existing with or mimicking rheumatic diseases such as SLE, RA and AS [10] . In this context, the observation that IL-17A is highly expressed in synovium of RA patients and that the cellular source is mainly CD4 + cells is particularly important [1114] . Differentiation and maintenance of Th17 cells in human is critically dependent on IL-1b, IL-6, TGF-b and IL-23 [15] . The finding in sarcoidosis of increased IL-12p40 (which is not only part of the Th1-inducing cytokine IL-12 but also of the Th17-inducing cytokine IL-23), together with increased IL-1b mRNA expression in lymph nodes [1618] , may therefore also point to a role of Th17 cells. Human Th17 cells comprise heterogeneous subsets. Next to IL-17A, these cells produce various other proinflammatory cytokines, including IL-17F, IL-22 and, in some conditions, IFN-g. IL-22 is a cytokine involved in mucosal immunity against extracellular pathogens and can also be produced independently of IL-17A, as was recently found in the context of psoriasis [1921] . Also IL-17A/IFN-g double-producing cells have been described [2224] , which could possibly be more pathogenic, since, for example, these cells preferentially cross the bloodbrain barrier in patients with multiple sclerosis.
Recently, sarcoidosis was suggested as a Th1/Th17 multi-system disorder [25] , based on the presence of IL-17 + CD4 T cells in sarcoid lung tissue and their ability to respond to the chemotactic stimulus chemokine (C-C motif) ligand 20. Moreover, IL-17A was expressed by macrophages infiltrating sarcoid tissue. However, the involvement of IL-22 or the recently identified pathogenic populations of IL-17A/IFN-g and IL-17A/IL-4 double-producing Th cells [26, 27] in sarcoidosis pathogenesis remains unknown.
Therefore, in this report we studied the presence of double-producing Th cells. Moreover, we investigated whether there would be granuloma-dependent differences in the presence of IL-22 and IL-17A + cells in granuloma containing compared with non-granulomatous lung mucosa biopsies obtained from sarcoidosis patients. Because of the heterogeneous cytokine profile of the Th17 subset, we analysed peripheral blood, bronchoalveolar lavage (BAL) cells and lung mucosal biopsies of newly diagnosed immunosuppressive drug-free Stage 1 or 2 sarcoidosis patients. Flow cytometric (FACS) analyses were performed for the expression of the main Th17 cytokines IL-17A, IL-17F and IL-22, along with IFN-g, TNF-a and IL-4 and immunohistochemistry for IL-17A and IL-22.
Materials and methods
Supplementary data are available at Rheumatology Online with more details regarding bronchoscopy procedure, peripheral blood mononuclear cell (PBMC) processing, flow cytometric analysis and immunohistochemical staining of lung mucosa biopsies.
Patients and healthy control subjects (Fig. 2B) . Importantly, large proportions of IL-17A + memory Th cells in BAL were also IFN-g + .
The frequency of IL-17A/IFN-g double-producing memory Th cells was therefore remarkably higher in BAL ($15%) than in peripheral blood ($1%) of sarcoidosis patients (Fig. 2C) . IL-17A/IL-4 double-producing cells were present at low, but detectable, proportions, representing a novel subpopulation (Fig. 2C) . In contrast, IL-17
+ cells were almost completely absent and proportions of IL-17A/ TNF-a or IL-17A/IL-17F double producers were present in the same ranges in BAL and peripheral blood from sarcoidosis patients (Fig. 2C and data not shown) . IL-17F/IFN-g double producers were virtually absent in BAL of sarcoidosis patients (Fig. 2D) T-cell population) in sarcoidosis, although the general observation is that these cells show a similar or a less pronounced cytokine pattern as CD4 + T cells do [29, 30] . Here, we observed that a substantial fraction of circulating CD8 + and g T cells produced IFN-g, whereby the proportions were significantly higher (P < 0.01) in sarcoidosis patients compared with healthy controls (see The presence of Th17 cytokines in memory Th cells in the BAL, representing the alveolar space of the lungs, prompted us to analyse T-cell cytokine expression in lung mucosal tissue of sarcoidosis patients. We investigated the presence of IL-17 + cells in lung mucosal biopsies from 27 sarcoidosis patients and 22 healthy controls (Fig. 3) . From the 27 biopsies from sarcoidosis patients, 10 contained clear granulomas (Fig. 3C ) and 17 were non-granulomatous, showing diffuse cellular infiltrates only (Fig. 3B) . IL-17A-expressing cells were particularly found in sarcoidosis lung biopsies containing granulomas. Low magnifications of immunohistochemical stainings revealed that IL-17 + cells were specifically present in areas of inflammatory cells surrounding granulomas, as well as within the granulomas (Fig. 3C ). In addition, we observed diffuse IL-17A staining within the granuloma areas (Fig. 3C) . IL-17 + cells were not detected in the epithelium.
Quantification of IL-17-expressing cells in biopsies from healthy controls and non-granulomatous and granulomacontaining biopsies from sarcoidosis patients showed that in all three groups the subepithelial area contained very few IL-17 + cells, although a trend of higher numbers was observed in granuloma-containing biopsies (P = 0.059, KruskalWallis test; Fig. 3D ). Importantly, in the entire lamina propria, the numbers of IL-17 + cells were significantly increased in granuloma-containing biopsies Fig. 3D ). By immunohistochemical double stainings for and CD3, the IL-17 + cells were characterized as T cells (Fig. 3E) .
In summary, we observed increased numbers of IL-17A + T cells in sarcoidosis in association with granulomas. Together with the presence of diffuse IL-17A staining in the granulomas, these findings suggest a role for IL-17A in granuloma formation or maintenance.
Increased subepithelial IL-22 + T cells in sarcoidosis lung biopsies containing granulomas
Finally, we investigated the presence of IL-22 + cells in the epithelium, subepithelium and lamina propria (Fig. 4) . The lamina propria areas, we did not detect significant differences between the three groups of biopsies (Fig. 4D) . Analyses of alveolar biopsies demonstrated the incidental presence of IL-22 + cells in healthy controls as well as in sarcoidosis patients, without significant differences between these groups. Immunohistochemical double stainings showed that IL-22 + cells were mainly CD3 + T cells, as illustrated in Fig. 4E . In those biopsies where IL-17 + cells
were detected in the lamina propria, we found an association with the presence of IL-22 + cells in the subepithelial area (r = 0.185; P = 0.05, Pearson's test, see Fig. S3 , available as supplementary data at Rheumatology Online). In summary, our findings show that sarcoidosis patients have a significant increase in IL-22-producing cells in the subepithelial area in the lung. Thus, their main localization is different from IL-17-producing cells, which are mainly localized around and within granulomas.
Discussion
The pathological mechanisms that control granulomatous inflammation in sarcoidosis are only poorly understood, but it is clear that cytokines play an important role in granuloma formation. To date, sarcoidosis pathogenesis has mainly been related to increased Th1 cytokines. In this report, we provide several lines of evidence for the involvement of pro-inflammatory Th17-lineage cytokines. Until now sarcoidosis has been considered a Th1-mediated multi-system disease and there has been convincing evidence reported for the role of Th1 cells in the pathogenesis of sarcoidosis over the past few years [1] . Thus, Th17 cells are clearly not the only effector cells capable of inducing or regulating granuloma pathogenesis. This would parallel findings in autoimmune uveitis and in experimental autoimmune encephalomyelitis, in which both Th1 and Th17 cells can drive tissue damage [6, 31] thought to be more pathogenic and have also been identified in Crohn's disease [32] and in coronary atherosclerosis [33] . Also our identification of IL-17A/IL-4 double-producing cells in sarcoidosis is of interest. Very few of these cells are present in the circulating memory T-cell populations in healthy individuals, but their proportions were reported to be significantly increased in patients with chronic asthma [34] . In this regard, it is very possible that these cells contribute to IL-4-induced pro-fibrotic features, such as fibroblast growth and collagen production, which are often observed in later stages of sarcoidosis [35] . [19, 21] . IL-17A has previously been implicated in various conditions characterized by granuloma formation. In a Mycobacterium bovis infection model, IL-17A expression was detected early after pulmonary infection and IL-17A-deficient mice showed impaired granuloma formation [36] . In humans living in regions with high prevalence of Mycobacterium tuberculosis infection, peripheral blood contains high frequencies of IL-17A + and IL-22 + memory
Th cells, which may have protective properties against tuberculosis [37] . In mouse models and in humans with active pulmonary tuberculosis, both IL-17A-and IL-22-producing CD4 + T cells and IL-17A + g T cells were
shown to contribute to the anti-mycobacterial immune response in human [7, 38] . Lung injury in a mouse model for chronic granulomatous disease with lethal aspergillosis was shown to involve unrestrained g T-cell reactivity and dominant production of IL-17A [39] . In Langerhans cell histiocytosis, which is accompanied by aggressive chronic granuloma formation, yet another cell population, dendritic cells, was shown to synthesize IL-17A [6] . An IL-17A-dependent pathway for dendritic cell fusion was identified, which was potentiated by IFN-g and led to giant cell formation. In this context, interesting parallels between Langerhans cell histiocytosis and sarcoidosis further include the presence of multinucleated giant cells [2, 6, 40] . The aetiology of sarcoidosis is still unknown. Epidemiological and histopathological data have been suggestive of occupational airborne antigens or infectious antigens underlying this disease, but until now attempts to link sarcoidosis to a causative pathogen have been difficult and remain controversial. It is therefore presently unclear which mechanisms would initiate a Th17 response in sarcoidosis. It is conceivable that the involvement of Th17 cells in sarcoidosis points to an autoimmune process that is comparable with various other IL-17A-driven autoimmunity disorders, such as autoimmune uveitis, RA, IBD or psoriasis. Future studies are required to determine putative genetic components that enhance IL-17A synthesis, e.g. IL-23R polymorphisms, which have also been associated with autoimmunity. As we observed diffuse IL-17A staining, it is very well possible that Th17-effector cells within granulomas are required to achieve local IL-17A concentrations that can activate various myeloid cell populations. Such a model would parallel the proposed role of local Th17 cells in the bone marrow, which may regulate myeloid development [41] . An alternative explanation for the observed diffuse IL-17A staining in granuloma may be that granuloma cells are a source for IL-17A, analogous to Langerhans cells in Langerhans cell histiocytosis [40] .
In summary, we provide evidence for the involvement of the Th17 lineage in sarcoidosis: IL-17A-expressing T cells were present in and around the granuloma and IL-22-expressing T cells were found in the subepithelial lamina propria in mucosal biopsies of sarcoidosis patients. This was accompanied by the presence of IL-17A + , IL-17A + IFN-g + and IL-17A + IL-4 + memory Th cells in BAL and by a significant increase in the proportions of these cells in the circulation. Therefore, IL-17A and IL-22 represent targets that may have clinical value in the treatment of sarcoidosis. In this context, it is promising that clinical trials of the fully human antibody, AIN457, in RA, psoriasis and non-infectious uveitis, show that targeting IL-17A interrupts inflammation and reduces disease activity [42] .
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